AR and prostate cancer: However, with prolonged treatment, there has revealed various molecular mechanisms leading to castration resistance in prostate cancer (CRPC), including aberrant overexpression of the AR gene, persistent activity of splice variants, and, notably, acquired somatic mutations6.